unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma with PD-L1 expression. In esophageal cancer, the agent is also approved by regulatory agencies in combination with platinum- and ...

Phase 3 trial showed Keytruda-Lenvima improves progression-free survival and response rates in HER2-negative ... is a rare type of cancer that occurs in the esophagus, the passageway that ...

Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal ... neoadjuvant therapy followed by esophagectomy for ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Impact of combined resection of pancreas on long-term survival in patients with gastric cancer. Preliminary results of the ALTER ... in patients with locally advanced or metastatic esophageal squamous ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but missing out on overall survival.

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

The ASPEN-06 data will be featured in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) earlier the same day.

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma ... Patients had no known HER2 positivity and an ECOG performance status of 0 or 1. Study enrollment occurred at 175 ...

HER2 low or negative breast cancer, small cell lung cancer, urothelial, gastric, pancreatic, castration resistant prostate and esophageal cancer. Safety endpoints include dose-limiting toxicities ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...